TWI763681B - 纖溶酶原在製備藥物中的用途 - Google Patents

纖溶酶原在製備藥物中的用途

Info

Publication number
TWI763681B
TWI763681B TW106120493A TW106120493A TWI763681B TW I763681 B TWI763681 B TW I763681B TW 106120493 A TW106120493 A TW 106120493A TW 106120493 A TW106120493 A TW 106120493A TW I763681 B TWI763681 B TW I763681B
Authority
TW
Taiwan
Prior art keywords
plasminogen
mice
group
pbs
control group
Prior art date
Application number
TW106120493A
Other languages
English (en)
Chinese (zh)
Other versions
TW201822807A (zh
Inventor
李季男
Original Assignee
大陸商深圳瑞健生命科學硏究院有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商深圳瑞健生命科學硏究院有限公司 filed Critical 大陸商深圳瑞健生命科學硏究院有限公司
Publication of TW201822807A publication Critical patent/TW201822807A/zh
Application granted granted Critical
Publication of TWI763681B publication Critical patent/TWI763681B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
TW106120493A 2016-12-15 2017-06-19 纖溶酶原在製備藥物中的用途 TWI763681B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2016/110171 2016-12-15
CNPCT/CN2016/110171 2016-12-15

Publications (2)

Publication Number Publication Date
TW201822807A TW201822807A (zh) 2018-07-01
TWI763681B true TWI763681B (zh) 2022-05-11

Family

ID=62557852

Family Applications (7)

Application Number Title Priority Date Filing Date
TW106120493A TWI763681B (zh) 2016-12-15 2017-06-19 纖溶酶原在製備藥物中的用途
TW106120494A TWI669130B (zh) 2016-12-15 2017-06-19 纖溶酶原在製備用於治療糖尿病的藥物上的用途
TW106120480A TWI738799B (zh) 2016-12-15 2017-06-19 纖溶酶原在製備藥物中的用途
TW106120482A TWI644682B (zh) 2016-12-15 2017-06-19 一種纖溶酶原在製備促進胰島細胞損傷修復的藥物上的用途
TW106120484A TW201822803A (zh) 2016-12-15 2017-06-19 一種抑制胰島β細胞凋亡的方法
TW106120481A TWI763680B (zh) 2016-12-15 2017-06-19 纖溶酶原在製備藥物中的用途
TW106120485A TWI642442B (zh) 2016-12-15 2017-06-19 纖溶酶原在製備降低胰高血糖素分泌的藥物上的用途

Family Applications After (6)

Application Number Title Priority Date Filing Date
TW106120494A TWI669130B (zh) 2016-12-15 2017-06-19 纖溶酶原在製備用於治療糖尿病的藥物上的用途
TW106120480A TWI738799B (zh) 2016-12-15 2017-06-19 纖溶酶原在製備藥物中的用途
TW106120482A TWI644682B (zh) 2016-12-15 2017-06-19 一種纖溶酶原在製備促進胰島細胞損傷修復的藥物上的用途
TW106120484A TW201822803A (zh) 2016-12-15 2017-06-19 一種抑制胰島β細胞凋亡的方法
TW106120481A TWI763680B (zh) 2016-12-15 2017-06-19 纖溶酶原在製備藥物中的用途
TW106120485A TWI642442B (zh) 2016-12-15 2017-06-19 纖溶酶原在製備降低胰高血糖素分泌的藥物上的用途

Country Status (9)

Country Link
US (4) US11311607B2 (enExample)
EP (4) EP3556390B1 (enExample)
JP (6) JP7171572B2 (enExample)
CN (4) CN110139667A (enExample)
CA (4) CA3047173A1 (enExample)
DK (1) DK3556383T5 (enExample)
ES (1) ES2981141T3 (enExample)
TW (7) TWI763681B (enExample)
WO (7) WO2018107704A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
DK3391902T5 (da) 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
CN110114080A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗皮肤纤维化的方法
JP7171572B2 (ja) * 2016-12-15 2022-11-15 タレンゲン インターナショナル リミテッド 糖尿病を治療するための新しい方法
TWI714862B (zh) * 2017-06-19 2021-01-01 大陸商深圳瑞健生命科學硏究院有限公司 一種調控glp-1/glp-1r的方法和藥物
CN111411072B (zh) * 2020-03-09 2022-10-11 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AU4661493A (en) 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
DK125693D0 (enExample) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
EP0824546B1 (en) 1995-04-26 2007-07-25 The Children's Medical Center Corporation Angiostatin fragments and methods of use
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US5955627A (en) 1996-12-16 1999-09-21 Kuraray Co., Ltd. Process for the preparation of cyclopropylacetylene derivatives
JP2002510209A (ja) 1997-06-26 2002-04-02 カロリンスカ イノベイションズ アクチボラゲット インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５
JP3561154B2 (ja) 1997-12-26 2004-09-02 株式会社東芝 放送受信装置および契約管理装置
US6728260B2 (en) 1998-06-26 2004-04-27 Intel Corporation Switch and/or router unit
JP4577992B2 (ja) 1998-09-29 2010-11-10 リューベン・リサーチ・アンド・デベロップメント・ベー・ゼット・ウェー 虚血性卒中の処置用の組成物を調製するための、α２抗プラスミンをインビボで減少する化合物の使用
WO2000044391A2 (en) 1999-01-28 2000-08-03 The Children's Medical Center Corporation Plasminogen kringle 4 region fragments and methods of use
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US20030014787P1 (en) 1999-03-31 2003-01-16 Olesen L. Pernille Floribunda rose variety 'POULfeld'
CA2385703A1 (en) 1999-10-07 2001-04-12 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI240723B (en) 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US6596785B2 (en) 2001-07-17 2003-07-22 Foamex L.P. Ink retaining foam structure
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
EP1472346A2 (de) 2002-02-06 2004-11-03 N-Zyme BioTec GmbH Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
EP2322203A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
US7075933B2 (en) 2003-08-01 2006-07-11 Nortel Networks, Ltd. Method and apparatus for implementing hub-and-spoke topology virtual private networks
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN1946352A (zh) 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
JP5026254B2 (ja) 2004-04-22 2012-09-12 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
CA2577782A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산
CN101227918A (zh) 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US8064439B2 (en) 2005-06-30 2011-11-22 Cisco Technology, Inc. Method and system for call processing
JP2009504762A (ja) 2005-08-17 2009-02-05 ワイス 置換インドール類およびそれらの使用方法
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
CN100529085C (zh) 2005-12-30 2009-08-19 上海新生源医药研究有限公司 重组人纤溶酶原Kringle 5(hk5)生产方法
CN101002888A (zh) 2006-01-16 2007-07-25 陈维森 复方糖尿康
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
EP2056864B1 (en) * 2006-08-28 2013-12-11 Omnio Healer AB Candidates against infection
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
BRPI0816560A2 (pt) * 2007-10-23 2015-09-01 Inst Med Molecular Design Inc Método de inibição de produção de pai-1 método para prevenção ou melhora de uma doença causada por uma super-produção de pai-1"
WO2009073471A1 (en) * 2007-11-29 2009-06-11 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US20090208448A1 (en) 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
JP2009196927A (ja) 2008-02-21 2009-09-03 Chemo Sero Therapeut Res Inst 血管障害に起因する網膜障害の進展阻害または治療剤
EP2424561A2 (en) * 2009-04-30 2012-03-07 Catherine Blondel Methods for treating ocular conditions
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
CN102250210B (zh) 2010-05-21 2014-05-28 厦门大学 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
ES2583082T3 (es) 2011-01-05 2016-09-19 Thrombogenics N.V. Variantes de plasminógeno y plasmina
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
WO2013024074A1 (en) * 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
US9718760B2 (en) 2012-10-31 2017-08-01 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
US9845363B2 (en) * 2013-08-13 2017-12-19 Sanofi Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof
KR102393711B1 (ko) * 2013-10-17 2022-05-04 더 제너럴 하스피탈 코포레이션 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물
CN104789544B (zh) 2014-01-16 2019-11-26 中国科学院福建物质结构研究所 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途
EP3233111B1 (en) 2014-12-19 2024-08-07 Kedrion Biopharma Inc. Pharmaceutical composition comprising plasminogen and uses thereof
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
TWI653982B (zh) 2015-12-18 2019-03-21 大陸商深圳瑞健生命科學研究院有限公司 Method for preventing or treating acute and chronic thrombosis
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
CN110366425A (zh) 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
JP7171572B2 (ja) 2016-12-15 2022-11-15 タレンゲン インターナショナル リミテッド 糖尿病を治療するための新しい方法
WO2019114839A1 (zh) 2017-12-15 2019-06-20 泰伦基国际有限公司 一种预防或治疗骨关节炎的方法和药物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 周漢明,夏敬勝 ."纖溶酶輔助治療2 型糖尿病62 例", 醫藥導報, 2 011年8月, 第30卷增刊, 35~36.; *
期刊 孫月娥等人, ."不同溶栓酶的特點、作用與臨床應用研究進展", 中國中藥雜誌, 第35卷第6期, 2010年3月, 794~798. *

Also Published As

Publication number Publication date
US11311607B2 (en) 2022-04-26
CN110366426A (zh) 2019-10-22
WO2018107701A1 (zh) 2018-06-21
TW201822800A (zh) 2018-07-01
EP3556390A1 (en) 2019-10-23
EP3556383A1 (en) 2019-10-23
EP3556384A4 (en) 2020-09-23
JP2020502140A (ja) 2020-01-23
JP2022166026A (ja) 2022-11-01
TW201822807A (zh) 2018-07-01
CA3047177A1 (en) 2018-06-21
WO2018107706A1 (zh) 2018-06-21
EP3556384B1 (en) 2024-04-10
TW201822803A (zh) 2018-07-01
WO2018107708A1 (zh) 2018-06-21
JP7554557B2 (ja) 2024-09-20
CA3047176C (en) 2021-11-30
CA3047176A1 (en) 2018-06-21
CN110198732A (zh) 2019-09-03
DK3556383T3 (da) 2024-05-13
WO2018107705A1 (zh) 2018-06-21
JP7175270B2 (ja) 2022-11-18
US20190314464A1 (en) 2019-10-17
US20190314465A1 (en) 2019-10-17
US11129880B2 (en) 2021-09-28
US20190307861A1 (en) 2019-10-10
WO2018107702A1 (zh) 2018-06-21
JP2022166028A (ja) 2022-11-01
TWI642442B (zh) 2018-12-01
TWI763680B (zh) 2022-05-11
EP3556383A4 (en) 2020-09-09
WO2018107703A1 (zh) 2018-06-21
WO2018107704A1 (zh) 2018-06-21
JP7554048B2 (ja) 2024-09-19
TWI738799B (zh) 2021-09-11
CA3047173A1 (en) 2018-06-21
EP3556384A1 (en) 2019-10-23
JP2020502150A (ja) 2020-01-23
JP7171572B2 (ja) 2022-11-15
EP3556392A1 (en) 2019-10-23
CA3047172A1 (en) 2018-06-21
CN110139667A (zh) 2019-08-16
TW201822808A (zh) 2018-07-01
EP3556390B1 (en) 2024-04-03
TW201822804A (zh) 2018-07-01
JP2020502151A (ja) 2020-01-23
EP3556390A4 (en) 2020-09-09
EP3556392B1 (en) 2024-04-17
DK3556383T5 (da) 2024-09-02
EP3556392A4 (en) 2020-09-23
CN110121357A (zh) 2019-08-13
JP2020510628A (ja) 2020-04-09
TWI644682B (zh) 2018-12-21
TW201822802A (zh) 2018-07-01
US20190314463A1 (en) 2019-10-17
TWI669130B (zh) 2019-08-21
ES2981141T3 (es) 2024-10-07
TW201822801A (zh) 2018-07-01
EP3556383B1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
TWI763681B (zh) 纖溶酶原在製備藥物中的用途
HK1257593A1 (zh) 治疗糖尿病的新药物及其用途
HK1257592A1 (en) Novel medicine for decreasing blood glucose and increasing sugar tolerance